STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #922 by analyst upside · 2026-06-27
ASMB
Assembly Biosciences, Inc.
Healthcare · Market Cap $530M · P/E 334.2x
ANALYST PRICE TARGET
+87.0%
implied upside to consensus target
Current Price $26.74
Consensus Target $50.0
Bull Target $62.0
Bear Target $43.0
Analysts Covering 4
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $16.81
52-Week High $39.71
YTD Return -20.8%
FUNDAMENTALS
Market Cap $530M
P/E Ratio (TTM) 334.2x
Forward P/E -12.7x
EPS (TTM) $0.08
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $71M
Profit Margin -9.0%
52-WEEK RANGE
52-Week Low $16.81
52-Week High $39.71
Current Price $26.74
Bear Target $43.0
Bull Target $62.0
● Now $26.74 ● Target $50.0
TRADING DATA
Avg Volume 162K
YTD Return -20.8%
Analyst Count 4
Consensus Buy
Upside to Target +87.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Assembly Biosciences, Inc. (ASMB) is currently trading at $26.74 with a Wall Street consensus price target of $50.0, implying potential upside of 87.0% over the next 12 months. 4 analysts currently cover ASMB, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $62.0, while the most cautious has a target of $43.0.

ASMB operates in the Healthcare sector with a market capitalisation of $530M. The stock is down 20.8% year-to-date and is currently trading near the lower end of its 52-week range of $16.81 – $39.71.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ASMB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Mizuho — Reiterated
Outperform → Outperform 2026-06-15 Building track record
Guggenheim reit
Buy → Buy 2026-05-28 62% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-04 31% win rate (48 calls)
Guggenheim — Reiterated
Buy → Buy 2026-04-06 62% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-26 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-12-22 31% win rate (48 calls)
Mizuho — Reiterated
Outperform → Outperform 2025-11-20 Building track record
HC Wainwright & Co. reit
Buy → Buy 2025-10-14 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →